Abstract
The mitotic spindle assembly checkpoint (SAC) is an essential control system of the eukaryotic cell cycle. This surveillance mechanism monitors the kinetochore, the multi-component complex that assembles on the centromeric DNA and attaches chromosomes to the microtubules of the spindle. The recruitment of mitotic checkpoint proteins to kinetochores that are not correctly attached to microtubules initiates a signalling cascade that results in the CDC20-dependent inhibition of the anaphase-promoting complex/cyclosome (APC/C). Mutations in the genes encoding for diverse SAC proteins have been identified in human tumour cells and associated with chromosome segregation and cancer progression. This work describes the current understanding on the organisation, function and structure of SAC components and shows this knowledge assists the identification of those that may constitute suitable targets for the clinical treatment of cancer.
Keywords: Mitotic spindle assembly checkpoint (SAC), genome instability, cell cycle, anticancer therapy, BUB1/BUBR1, CDC20-MAD2, CENP-E, fragment-based screening
Current Cancer Drug Targets
Title: Assessment of the Mitotic Spindle Assembly Checkpoint (SAC) as the Target of Anticancer Therapies
Volume: 9 Issue: 2
Author(s): Victor M. Bolanos-Garcia
Affiliation:
Keywords: Mitotic spindle assembly checkpoint (SAC), genome instability, cell cycle, anticancer therapy, BUB1/BUBR1, CDC20-MAD2, CENP-E, fragment-based screening
Abstract: The mitotic spindle assembly checkpoint (SAC) is an essential control system of the eukaryotic cell cycle. This surveillance mechanism monitors the kinetochore, the multi-component complex that assembles on the centromeric DNA and attaches chromosomes to the microtubules of the spindle. The recruitment of mitotic checkpoint proteins to kinetochores that are not correctly attached to microtubules initiates a signalling cascade that results in the CDC20-dependent inhibition of the anaphase-promoting complex/cyclosome (APC/C). Mutations in the genes encoding for diverse SAC proteins have been identified in human tumour cells and associated with chromosome segregation and cancer progression. This work describes the current understanding on the organisation, function and structure of SAC components and shows this knowledge assists the identification of those that may constitute suitable targets for the clinical treatment of cancer.
Export Options
About this article
Cite this article as:
Bolanos-Garcia M. Victor, Assessment of the Mitotic Spindle Assembly Checkpoint (SAC) as the Target of Anticancer Therapies, Current Cancer Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/156800909787580980
DOI https://dx.doi.org/10.2174/156800909787580980 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Reactive Oxygen Species, Cancer and Anti-Cancer Therapies
Current Chemical Biology The Current Status of Novel PET Radio-Pharmaceuticals in Radiotherapy Treatment Planning of Glioma
Current Pharmaceutical Biotechnology Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry In vitro activity and Cytotoxicity of Crocus sativus Extract against Leihmania Major (MRHO/IR/75/ER)
Infectious Disorders - Drug Targets Possible Binding Mode Analysis of Pyrazolo-triazole Hybrids as Potential Anticancer Agents through Validated Molecular Docking and 3D-QSAR Modeling Approaches
Letters in Drug Design & Discovery Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Current Drug Targets Quercetin Promotes Cell Cycle Arrest and Apoptosis and Attenuates the Proliferation of Human Chronic Myeloid Leukemia Cell Line-K562 Through Interaction with HSPs (70 and 90), MAT2A and FOXM1
Anti-Cancer Agents in Medicinal Chemistry Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Polysaccharide-K (PSK) in Cancer - Old Story, New Possibilities?
Current Medicinal Chemistry Editorial [Hot topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Smoking-Related Cardiovascular Diseases (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Pharmaceutical Design Antitumor Activity of Copper (I)–Nicotinate Complex and Autophagy Modulation in HCC1806 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Anticoagulant and Fibrinolytic Drugs – Possible Agents in Treatment of Lung Cancer?
Anti-Cancer Agents in Medicinal Chemistry Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design